These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37350788)

  • 21. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
    Mulder AM; Carragher B; Towne V; Meng Y; Wang Y; Dieter L; Potter CS; Washabaugh MW; Sitrin RD; Zhao Q
    PLoS One; 2012; 7(4):e33235. PubMed ID: 22493667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status and future directions of fish vaccines employing virus-like particles.
    Jeong KH; Kim HJ; Kim HJ
    Fish Shellfish Immunol; 2020 May; 100():49-57. PubMed ID: 32130976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.
    Masavuli MG; Wijesundara DK; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Microbiol; 2017; 8():2413. PubMed ID: 29259601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses.
    Chua BY; Johnson D; Tan A; Earnest-Silveira L; Sekiya T; Chin R; Torresi J; Jackson DC
    PLoS One; 2012; 7(10):e47492. PubMed ID: 23091628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    O'Kennedy MM; Abolnik C; Smith T; Motlou T; Goosen K; Sepotokele KM; Roth R; du Preez I; Truyts A; Stark HC; Magwaza M; Mahanjana O; Verschoor JA; Moore PL; Lemmer Y
    Vaccine; 2023 Mar; 41(13):2261-2269. PubMed ID: 36868876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virus-Like Particle-Templated Silica-Adjuvanted Nanovaccines with Enhanced Humoral and Cellular Immunity.
    Li M; Liang Z; Chen C; Yu G; Yao Z; Guo Y; Zhang L; Bao H; Fu D; Yang X; Wang H; Xue C; Sun B
    ACS Nano; 2022 Jul; 16(7):10482-10495. PubMed ID: 35763693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virus-like particles: potential veterinary vaccine immunogens.
    Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
    Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
    Yang JR; Chen CY; Kuo CY; Cheng CY; Lee MS; Cheng MC; Yang YC; Wu CY; Wu HS; Liu MT; Hsiao PW
    Antiviral Res; 2016 Feb; 126():8-17. PubMed ID: 26593980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.
    Joe CCD; Chatterjee S; Lovrecz G; Adams TE; Thaysen-Andersen M; Walsh R; Locarnini SA; Smooker P; Netter HJ
    Vaccine; 2020 May; 38(22):3892-3901. PubMed ID: 32284273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?
    Chu KB; Quan FS
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System.
    Xu R; Shi M; Li J; Song P; Li N
    Front Bioeng Biotechnol; 2020; 8():862. PubMed ID: 32850726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
    Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
    J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subunit Protein Vaccine Delivery System for Tuberculosis Based on Hepatitis B Virus Core VLP (HBc-VLP) Particles.
    Dhanasooraj D; Kumar RA; Mundayoor S
    Methods Mol Biol; 2016; 1404():377-392. PubMed ID: 27076312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells.
    Suphatrakul A; Yasanga T; Keelapang P; Sriburi R; Roytrakul T; Pulmanausahakul R; Utaipat U; Kawilapan Y; Puttikhunt C; Kasinrerk W; Yoksan S; Auewarakul P; Malasit P; Charoensri N; Sittisombut N
    Vaccine; 2015 Oct; 33(42):5613-5622. PubMed ID: 26382602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Efficient and Scalable Method for the Production of Immunogenic SARS-CoV-2 Virus-like Particles (VLP) from a Mammalian Suspension Cell Line.
    Hirschberg S; Ghazaani F; Ben Amor G; Pydde M; Nagel A; Germani S; Monica L; Schlör A; Bauer H; Hornung J; Voetz M; Dwai Y; Scheer B; Ringel F; Kamal-Eddin O; Harms C; Füner J; Adrian L; Pruß A; Schulze-Forster K; Hanack K; Kamhieh-Milz J
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
    Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
    Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platforms, advances, and technical challenges in virus-like particles-based vaccines.
    Gupta R; Arora K; Roy SS; Joseph A; Rastogi R; Arora NM; Kundu PK
    Front Immunol; 2023; 14():1123805. PubMed ID: 36845125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.